Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Tourmaline Bio, Inc. - Common Stock
(NQ:
TRML
)
47.98
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 27, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tourmaline Bio, Inc. - Common Stock
< Previous
1
2
3
Next >
Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
August 13, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
May 23, 2025
Via
Benzinga
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings
↗
May 20, 2025
Via
Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
May 20, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
Via
Chartmill
Trip.com Posts Weak Earnings, Joins Vipshop, Viking Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
May 20, 2025
Via
Benzinga
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease
May 20, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
May 19, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 02, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
What's going on in today's pre-market session
↗
April 17, 2025
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
April 17, 2025
Via
Benzinga
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
March 13, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
↗
March 06, 2025
Via
Benzinga
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
March 03, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
February 24, 2025
Via
Benzinga
Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference
January 27, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
January 10, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
December 10, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
November 14, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 07, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Present at Upcoming Investor Conferences
October 31, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
October 15, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
October 11, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
October 08, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Present at Upcoming Investor Conferences
September 03, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
TRML Stock Earnings: Tourmaline Bio Beats EPS for Q2 2024
↗
August 08, 2024
TRML stock results show that Tourmaline Bio beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 08, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
August 02, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
June 27, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
May 23, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
May 16, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
